HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...

Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...

“ [Trump’s plans] will come at the expense of potentially larger budget deficits, potentially larger debt and there is also ...

Most U.S. stocks ticked higher to recover some of their sharp slide from last week. The S&P 500 rose 0.4% Monday for its first gain in three days. The Dow Jones Industrial Average slipped 0.1%, and ...

U.S. stocks were mixed after the close on Monday, as gains in the Consumer Goods, Telecoms and Oil & Gas sectors led shares higher while losses in the Healthcare, Industrials and Consumer Services ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.